Lakefront Biotherapeutics | GLPG - Current Assets


Lakefront Biotherapeutics reported EUR3.06B in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
argenx SE USD 6.9B 1.07B Dec/2025
AstraZeneca USD 29.61B 890M Mar/2026
Biogen USD 9.19B 216.3M Mar/2026
Genmab DKK 2.88B 1.59B Dec/2025
Gilead Sciences USD 18.64B 1.25B Mar/2026
GlaxoSmithKline GBP 17.76B 251M Mar/2026
GRIFOLS EUR 5.25B 180M Mar/2026
Hikma Pharmaceutical USD 2.64B 86M Dec/2025
Incyte USD 5.48B 460.36M Mar/2026
Merck EUR 14.16B 932M Mar/2026
Neurocrine Biosciences USD 2.44B 86.6M Mar/2026
Novartis USD 26.61B 3.85B Mar/2026
Roche Holding CHF 38.73B 3.03B Dec/2025
Sanofi EUR 30.16B 789M Mar/2026
UCB EUR 6.05B 733M Dec/2025
Vertex Pharmaceuticals USD 11.73B 529.3M Mar/2026